Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog
A slow-release formulation of the luteinizing hormone releasing hormone (LH-RH)analog(TAP-144-SR) was administered in 6 cases of prostatic cancer. Five were untreated cases, 3 of moderately-differentiated and 2 of poorly-differentiated cancers (four D2 and one C, NX), the other (D2) was under contro...
| Veröffentlicht in: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 34(1988), 3 vom: 15. März, Seite 555-60 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , |
| Format: | Aufsatz |
| Sprache: | Japanese |
| Veröffentlicht: |
1988
|
| Zugriff auf das übergeordnete Werk: | Hinyokika kiyo. Acta urologica Japonica |
| Schlagworte: | English Abstract Journal Article Antineoplastic Agents Delayed-Action Preparations Gonadotropin-Releasing Hormone 33515-09-2 Testosterone 3XMK78S47O Luteinizing Hormone 9002-67-9 mehr... |
| Zusammenfassung: | A slow-release formulation of the luteinizing hormone releasing hormone (LH-RH)analog(TAP-144-SR) was administered in 6 cases of prostatic cancer. Five were untreated cases, 3 of moderately-differentiated and 2 of poorly-differentiated cancers (four D2 and one C, NX), the other (D2) was under control by another LH-RH analog. The plasma level of luteinizing hormone and follicle stimulating hormone fell below normal, and the plasma testosterone was less than 1 ng/ml by four weeks after start of treatment. According to the National Prostatic Cancer Project Criteria, 2 of the untreated cases showed a partial response and 3 of the untreated ones showed a stable response, one of which underwent transurethral resection later. The pretreated case still continued controlled more than 4 months. No side effect was noticed |
|---|---|
| Beschreibung: | Date Completed 11.08.1988 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
| ISSN: | 0018-1994 |